Can Moderna (MRNA) Stock Reach $77?

Key Takeaways

• Target in focus: Piper Sandler's $77 price target represents roughly 40% upside from Moderna's recent close of $55.14, making it the most bullish Wall Street objective currently on the table.
• Strongest bullish factors: An imminent FDA decision on the company's mRNA flu vaccine (mFLUSIVA), advancing oncology pipeline assets including the closely watched intismeran autogene melanoma program, and a fortified balance sheet with approximately $5.96 billion in pro forma cash.
• Biggest obstacles: Declining COVID-19 vaccine revenue, persistent net losses expected through at least 2027, and the recent Phase 3 norovirus vaccine trial setback that delays a key pipeline catalyst.
• Key technical levels: The $52–$55 zone represents important support from the prior trading range, while $60 and $67 serve as intermediate resistance levels before $77 comes into view.
• Bottom line: Reaching $77 is plausible but would likely require positive melanoma Phase 3 data, successful commercial execution across new vaccine launches, and a broader market willing to reward pipeline-stage biotech stories.

Why Investors Are Watching the $77 Level

Moderna, Inc. (MRNA) has delivered a remarkable rally in 2026, climbing roughly 86% year-to-date. Yet the stock sits approximately 35% below its 52-week high of $85.60, reached in early July, following a sharp pullback driven by profit-taking and a disappointing norovirus vaccine trial update. Against this backdrop, Piper Sandler's reiterated $77 price target—the highest among major Wall Street analysts—has become a focal point for investors trying to gauge whether the recent sell-off represents a buying opportunity or the beginning of a deeper reset. The $77 level sits well above the analyst consensus average of approximately $40–$50, making it a distinctly bullish scenario that would require nearly everything to go right for the Cambridge, Massachusetts-based biotechnology company.

What Could Drive Moderna Toward $77

The most immediate catalyst is the FDA's decision on mFLUSIVA, Moderna's mRNA-based seasonal influenza vaccine, expected by August 5, 2026. A favorable advisory committee voted unanimously 9-0 in June that the vaccine's benefits outweigh its risks for adults aged 50 and older. Approval would mark the first mRNA flu vaccine in the United States and serve as critical validation that Moderna's platform can succeed beyond COVID-19. While flu vaccine revenue alone may not transform the financial picture overnight, it would meaningfully diversify the company's revenue base and de-risk the broader pipeline.

Longer-term, the oncology pipeline represents the single most important driver for sustained share price appreciation. The Phase 3 INTERPATH-001 trial evaluating intismeran autogene in combination with Merck's KEYTRUDA as adjuvant therapy for melanoma is expected to deliver interim data later this year. Positive results could position the therapy for a potential blockbuster approval in 2027 and unlock the broader cancer vaccine opportunity. Piper Sandler has explicitly cited this program as central to its Overweight rating and $77 target.

Moderna's balance sheet provides a meaningful runway. After closing the second quarter with $6.9 billion in cash and paying a $950 million litigation settlement in July, pro forma cash stands at roughly $5.96 billion—more than enough to fund operations through key clinical readouts without imminent dilution risk. Management has also improved its 2026 operating-expense outlook by approximately $200 million, signaling growing cost discipline.

What Could Prevent the Move

Moderna remains deeply unprofitable. The company posted a GAAP net loss of approximately $782 million in the second quarter of 2026, and consensus estimates project negative earnings per share (EPS) through at least 2027. Revenue remains heavily dependent on declining COVID-19 vaccine sales, with Q2 Spikevax revenue of just $91 million. While management guided for approximately 10% revenue growth in 2026, the base from which that growth starts is modest relative to the company's $22 billion market capitalization. The stock trades at a price-to-sales (P/S) ratio of roughly 9.8x—below the biotech industry average but well above the peer group average of approximately 5.3x.

The Phase 3 norovirus vaccine trial (mRNA-1403) failed to meet statistical criteria for early success at its interim analysis, forcing Moderna to add another participant cohort and extending the timeline. This setback underscores the binary nature of clinical-stage biotech investing: pipeline disappointments can rapidly reverse sentiment. Additionally, insider selling activity—including President Stephen Hoge's sale of $3.6 million in shares at $67.60—has introduced a note of caution, even if conducted under pre-planned 10b5-1 trading plans.

Analyst Sentiment Remains Divided

Wall Street is far from unified on Moderna's prospects. Of 23 analysts covering the stock, only two rate it a Buy or equivalent, while 16 recommend Hold and five rate it Sell or Underperform. The consensus rating sits at Hold/Reduce with an average price target near $40–$50, implying potential downside from current levels. At the bullish end, Piper Sandler targets $77, while Goldman Sachs raised its target to $67 but maintained a Neutral rating. At the bearish end, Wolfe Research holds an Underperform rating with a $25 target, and Morgan Stanley maintains an Equal-Weight rating at $39. The wide dispersion—from $25 to $77—reflects profound disagreement about whether Moderna's mRNA platform can ultimately justify its valuation.

Technical Levels That Matter

From a technical perspective, the $52–$55 zone represents a critical support area that aligns with the top of the April-to-June trading range and served as the launch point for the stock's Science Day breakout. The 200-day moving average near $52.64 reinforces this level. Holding above this zone would keep the broader recovery structure intact. On the upside, $60 marks the first psychological hurdle, followed by $67—near Goldman Sachs's target and the level where insider selling occurred. The $77 target itself coincides with Piper Sandler's objective and sits just below the stock's July highs, meaning any move toward that level would represent a nearly complete recovery from the recent pullback. The 52-week high of $85.60 remains the ultimate resistance reference point.

AI Daily Buy/Sell Signals

Navigating a volatile biotech stock like Moderna requires timely, data-driven decision-making. Tickeron's AI Daily Buy/Sell Signals leverage artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical patterns, and AI-driven analysis. Traders can use these signals to identify emerging opportunities, track existing positions, and stay ahead of changing market trends without manually scanning charts. For those seeking an edge in fast-moving markets, AI-powered signal tools offer a way to process more information in less time. Explore Tickeron's AI Daily Buy/Sell Signals to see how machine learning can support your trading workflow.

Final Assessment

The question of whether Moderna can reach $77 hinges on a sequence of binary outcomes that remain unresolved. The bullish thesis is anchored in platform validation—the idea that mRNA technology can generate multiple approved products across infectious disease, oncology, and rare disease. An FDA approval for mFLUSIVA would bolster that case, but the game-changing catalyst is the melanoma Phase 3 readout expected later in 2026. Positive data there could fundamentally re-rate the stock by proving the oncology thesis. On the other side, declining COVID revenue, persistent losses, pipeline setbacks like the norovirus trial, and a skeptical analyst consensus all weigh against a swift return to $77. Investors should monitor the August 5 FDA decision, melanoma data timing, and quarterly revenue trends as the most important signposts. While $77 is achievable under an optimistic scenario, the path requires clinical success, commercial execution, and sustained investor patience—a combination that cannot be taken for granted in the biotechnology sector.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations